Outcome Protocol · #18

Appetite Suppression

Reduce appetite and support weight management goals

Peptides in this protocol

PT-141 (Bremelanotide)

Sexual Function & Libido

Secondary
Safe default
1mg · daily (investigational)
Experimental upper
1.75mg · daily (investigational)
Low-dose bremelanotide for appetite/weight maintenance is investigational (BMT-801 Phase 2 only). Daily melanocortin dosing materially raises hyperpigmentation risk above the 8-dose/month HSDD threshold.
Route
SubQ

Retatrutide

GLP-1 Receptor Agonists

Primary
Safe default
6mg · weekly
Experimental upper
12mg · weekly
Route
SubQ

Semaglutide

GLP-1 Receptor Agonists

Secondary
Safe default
2.4mg · weekly
Route
SubQ

Tirzepatide

GLP-1 Receptor Agonists

Secondary
Safe default
15mg · weekly
Experimental upper
15mg · weekly
Route
SubQ

Related peptide categories

Build the Appetite Suppression stack in the Lab

Drag the peptides above into Pinned.life's Lab Sandbox to see live serum-level simulations, peak-overlap warnings, and drug-peptide interaction guards. Commit the stack to a real protocol when you're ready.

Open the Lab →Browse all peptides